Myomo, Inc. introduced a new mobile application for its MyoPro upper‑limb orthosis on April 20, 2026. The app is available on both the Google Play Store and the Apple App Store and lets clinicians and patients customize EMG settings remotely or in person, monitor device usage, and view real‑time muscle‑activity visualizations. “For clinicians, the Myomo Mobile App is designed to simplify device configuration and improve visibility into patient use, whether care is delivered in clinic or remotely,” said Paul R. Gudonis, Myomo’s Chairman and Chief Executive Officer. “For patients, the app helps make muscle activity more understandable and encourages confidence through real‑time feedback and easy access to training resources.”
The MyoPro system is the only U.S. device that restores activities of daily living by sensing EMG signals, and the new app expands that value proposition into a connected digital ecosystem. By capturing usage data and providing interactive feedback, the app is expected to improve patient adherence, engagement, and the quality of data available for research, development, and reimbursement claims.
In the fourth quarter of fiscal 2025, Myomo reported revenue of $11.4 million, beating the Street estimate of $10.4 million and reflecting continued demand for the MyoPro orthosis. The company’s revenue grew 26 % year‑over‑year, but the quarter also highlighted financial challenges: a net loss of $15.6 million versus $6.2 million in 2024, and a gross margin of 68.6 % compared with 71.4 % in the prior year. Margin compression was driven by a lower average selling price, an unfavorable shift in overhead capitalized to inventory, and higher warranty costs.
Fiscal 2026 guidance fell short of Wall Street expectations, prompting a reassessment of the company’s near‑term outlook. Management has not announced any strategic changes beyond the app launch, but the guidance miss signals caution about future revenue growth and profitability.
Additional developments include a network participation agreement with Elevance Health that expands coverage to 45 million additional members, bringing the total covered lives under commercial plans to over 80 million. William Febbo was appointed to Myomo’s board of directors. The company’s GF Score is 59/100, and it ranks 1 out of 10 in profitability, underscoring the need to balance growth initiatives with cost discipline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.